The Pharma
Perspective.
Clear, insightful conversations on the ideas, challenges, and innovations shaping the pharmaceutical industry. For consultants, researchers, and industry professionals who want to think more clearly about pharma.
Start here.
Not sure where to begin? This episode is a great introduction to the kind of conversations we have on The Pharma Perspective.
Is Raising the NICE Threshold Bad for NHS Patients?
Karl Claxton — Professor of Economics, University of York
One of the most cited health economists in the world joins the show to discuss what the NICE cost-effectiveness threshold really means for patients — and why the debate around raising it is more complex than it appears.
Every conversation.
From drug regulation to career advice — each episode explores a different facet of the pharma world.
The conversations that matter.
Leading researchers, industry executives, and policy experts sharing perspectives you won't find anywhere else.
About Mirko.
With over a decade of experience across IQVIA, Parexel, and Gilead Sciences, Mirko brings a uniquely grounded perspective to every conversation. He's worked on both sides of the HTA divide — building the models and navigating the submissions — and now hosts the world's largest YouTube channel dedicated to health economics.
Connect on LinkedInNever miss an
episode.
Subscribe on your favourite platform and get new episodes every month.